incretin mimetic agents glp 1 receptor agonists Incretins: How we got here, where we're at and what is coming next GLP-1 receptor agonists and next-generation

For patients interested in GLP-1 medications specifically for type 2 diabetes rather than weight management, the path is often simpler

In type 2 diabetes trials (the SUSTAIN program), Ozempic produced an average weight loss of around 4.5 kg to 6.5 kg (roughly 10 to 14 lbs) over 52 weeks, depending on the dose

In obesity medicine, the emphasis expands to include behavioral factors, long-term adherence, and patient motivation

doi: 10.1038/nrgastro.2016.181 14 SodhiMRezaeianzadehRKezouhAEtminanM

J Bras Nefrol

Orally administered semaglutide versus GLP-1 RAs in patients with type 2 diabetes previously receiving 12 oral antidiabetics: systematic review and network meta-analysis